Skip to main content
. 2018 Dec 28;9(102):37700–37714. doi: 10.18632/oncotarget.26491

Figure 6. STRO-001 significantly reduces tumor burden in the ARP-1 myeloma model.

Figure 6

SCID mice were inoculated with ARP-1 MM tumor cells by intravenous injection. Mice were treated weekly with 3 mg/kg STRO-001 beginning at 14 days post-tumor inoculation for one month. Naïve control mice were not inoculated with tumor cells and did not receive treatment. (A) Kaplan-Meier survival curves in response to treatment. (B) Quantification of hCD138+ cells in the bone marrow depicted as percent relative to vehicle control (set as 100% maximum) on day 49. (C, D) Quantification of weights and representative images of internal visceral tumors in and around the ovary and kidney on day 49. Graphs are shown as average values ± SEM.